GlassScriptPhysician profile
Stephen Angelo Boveri
NPI 1386679660
$5,472.40
in general payments reported to CMS, 2019-2025
37 companies · $670 in 2025
The $670 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $360 · 2021: $1,180 · 2022: $961 · 2023: $902 · 2024: $557 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.03 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $609.30 | 2021-2025 | |
| Evofem Biosciences, INC. | $433.82 | 2020-2025 | Phexxi, Solosec, Phexx |
| Allergan, INC. | $346.62 | 2019-2021 | |
| Novo Nordisk INC | $251.25 | 2019-2025 | Wegovy |
| Pfizer INC. | $211.61 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $203.01 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $192.97 | 2019-2022 | |
| Daiichi Sankyo INC. | $189.13 | 2019-2022 | |
| Hologic Sales and Service, LLC | $170.53 | 2021-2024 | Novasure, Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $168.37 | 2019-2025 | Slynd |
| Organon LLC | $149.83 | 2021-2025 | Nexplanon |
| Avion Pharmaceuticals | $117.91 | 2020-2023 | Balcoltra |
| Shield Therapeutics INC | $103.83 | 2022-2024 | Accrufer |
| Myovant Sciences INC. | $98.40 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $73.95 | 2021-2022 | |
| Exact Sciences Corporation | $72.44 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Agile Therapeutics, INC. | $68.02 | 2021-2023 | Twirla |
| Lilly USA, LLC | $67.93 | 2024-2025 | Zepbound, Mounjaro |
| Duchesnay USA Incorporated | $64.37 | 2019 | |
| Astellas Pharma US INC | $58.41 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $50.08 | 2021-2024 | Ova1 |
| Merck Sharp & Dohme LLC | $48.76 | 2020-2025 | Bridion |
| Endo Pharmaceuticals INC. | $47.50 | 2020-2021 | |
| Meditrina | $41.73 | 2022 | |
| Gynesonics, INC. | $34.15 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $28.27 | 2019-2020 | |
| Millicent US INC | $20.40 | 2025 | Intrarosa |
| Ascend Therapeutics US, LLC | $19.44 | 2024 | |
| Minerva Surgical, INC | $18.74 | 2023 | |
| Coopersurgical, INC. | $18.30 | 2025 | Endosee |
| Biohaven Pharmaceuticals, INC. | $16.12 | 2021 | |
| Amgen INC. | $15.40 | 2024 | Evenity, Prolia |
| Vertical Pharmaceuticals, LLC | $15.12 | 2019 | |
| Boston Scientific Corporation | $14.84 | 2025 | Bulkamid |
| Axonics, INC. | $14.07 | 2023 | Bulkamid |
| Medicem INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Boveri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.